Natera Acquires Foresight Diagnostics

Quest Diagnostics Acquires Haystack Oncology

April 27, 2023

Healthcare Services

Quest Diagnostics has agreed to acquire Haystack Oncology in an all-cash transaction valued at $300 million at closing plus up to $150 million in potential milestones. The acquisition adds Haystack's sensitive ctDNA-based minimal residual disease (MRD) liquid biopsy technology to Quest's oncology, genomics and pathology capabilities to expand clinical lab services for MRD testing beginning in 2024.

Fulgent Genetics Acquires Fulgent Pharma

November 7, 2022

Biotechnology

Fulgent Genetics completed the acquisition of Fulgent Pharma Holdings for approximately $100 million in a combination of cash and Fulgent common stock. The deal integrates Fulgent Pharma’s nanoencapsulation drug-delivery platform and clinical-stage oncology pipeline with Fulgent Genetics’ diagnostics capabilities to create a vertically integrated precision-medicine offering focused on cancer.

Fulgent Genetics Acquires Inform Diagnostics from Avista Capital Partners

April 18, 2022

Healthcare Services

Fulgent Genetics agreed to acquire Inform Diagnostics, a leading national independent pathology laboratory headquartered in Irving, Texas, for approximately $170 million. The acquisition from Avista Capital Partners expands Fulgent’s pathology and anatomic testing menu, adds nationwide commercial and managed-care relationships, and broadens its geographic lab footprint to support cross-selling of genomic and pathology services.

Sherlock Biosciences Acquires Sense Biodetection

February 1, 2023

Biotechnology

Sherlock Biosciences has acquired Sense Biodetection to accelerate commercialization of CRISPR-enabled, instrument-free molecular diagnostics by integrating Sense’s Veros rapid, instrument-free test platform, chemistry and manufacturing capabilities into Sherlock’s platform. Terms were not disclosed; Sense is headquartered in Oxford, United Kingdom with additional facilities in Cambridge (UK) and Milford, Massachusetts.

Nephros Acquires Substantially All Assets of GenArraytion, Inc.

July 12, 2021

Biotechnology

Nephros, Inc. (Nasdaq: NEPH) acquired substantially all of the assets of GenArraytion, Inc., a Rockville, Maryland-based developer of infectious disease PCR assays and multiplexing technology. The acquisition gives Nephros access to GenArraytion's MultiFLEX bioassays and other proprietary assays, which will be integrated into Nephros' Pathogen Detection Systems platform, and GenArraytion's CEO Dr. R. Paul Schaudies will partner with Nephros' pathogen detection leadership.

Eurobio Scientific Acquires GenDx (Genome Diagnostics B.V.)

October 4, 2022

Biotechnology

Paris-based Eurobio Scientific has acquired all outstanding shares of Dutch transplant diagnostics specialist GenDx (Genome Diagnostics B.V.), following a share purchase agreement signed on August 17. The acquisition expands Eurobio's molecular diagnostics portfolio in transplantation and secures the company legacy with proceeds funding a GenDx foundation established by the founders.